2.
Diagnostic performances of CA125, HE4, ROMA and CPH-I for discrimination of ovarian cancer from other subtypes
| Group | Tests | AUC(95%CI) | SN(%) | SP(%) | PPV(%) | NPV(%) |
| OC: Ovarian cancer; BOT: Borderline ovarian tumor; Non-EOC: Non-epithelial ovarian cancer; EOC: Epithelial ovarian cancer; AUC: Area under curve; SN: Sensitivity; SP: Specificity; PPV: Positive predictive value; NPV: Negative predictive value. | ||||||
| OC+BOT (n=188) vs Benign (n=531) | ||||||
| CA125 | 0.792 (0.751, 0.833) | 70.2 | 72.9 | 47.8 | 874 | |
| HE4 | 0.854(0.817, 0.891) | 56.9 | 94.4 | 78.1 | 86.1 | |
| ROMA | 0.856 (0.819, 0.893) | 69.1 | 87.6 | 66.3 | 88.9 | |
| CPH-I | 0.854 (0.818, 0.890) | 63.8 | 94.7 | 81.1 | 88.1 | |
| EOC (n=119)vs Benign (n=531) | ||||||
| CA125 | 0.888 (0.849, 0.928) | 84.0 | 72.9 | 41.0 | 95.3 | |
| HE4 | 0.946(0.915, 0.977) | 79.8 | 94.4 | 76.0 | 95.4 | |
| ROMA | 0.947 (0.916, 0.978) | 87.4 | 87.6 | 61.2 | 96.9 | |
| CPH-I | 0.943 (0.913, 0.974) | 84.9 | 94.7 | 78.3 | 96.5 | |
| EOC (n=119) vs Non-EOC+BOT (n=69) | ||||||
| CA125 | 0.836(0.778, 0.893) | 84.0 | 53.6 | 75.8 | 66.1 | |
| HE4 | 0.886 (0.839, 0.934) | 79.8 | 82.6 | 88.8 | 70.4 | |
| ROMA | 0.889 (0.842, 0.937) | 87.4 | 62.3 | 80.0 | 74.1 | |
| CPH-I | 0.888 (0.841, 0.934) | 84.9 | 72.5 | 84.2 | 73.5 | |
| Non-EOC+BOT (n=69) vs Benign (n=531) | ||||||
| CA125 | 0.625 (0.557, 0.694) | 46.4 | 72.9 | 18.2 | 91.3 | |
| HE4 | 0.696 (0.625, 0.767) | 17.4 | 94.4 | 28.6 | 89.8 | |
| ROMA | 0.700(0.629, 0.770) | 37.7 | 87.6 | 28.3 | 91.5 | |
| CPH-I | 0.700(0.633, 0.767) | 27.5 | 94.7 | 40.4 | 91.0 | |